Publicly traded medical firm Semler Scientific has reportedly pivoted away from its aggressive Bitcoin treasury playbook after reporting a $22 million impairment loss. The financial hit, largely driven by Bitcoin’s price volatility, underscores the accounting challenges faced by U.S. public companies. Under current regulatory standards, firms must report losses when the value of their crypto assets drops below the purchase price, creating significant volatility in quarterly earnings reports regardless of whether the assets are sold.
In an effort to strengthen its balance sheet, the company has cleared its outstanding debt with Coinbase, the primary custodian for its digital assets. Disclosures as of July 23 indicate that the firm maintains a balance of approximately 760 BTC. This deleveraging move suggests that while the company remains a holder, the 'MicroStrategy model' of continuous, aggressive accumulation may be proving too risky for mid-cap corporations without massive cash reserves.
Investors should view this as a test case for institutional adoption in the U.S. market. While the upcoming shift toward fair-value accounting by the FASB may eventually offer relief to corporate treasurers, the current environment remains punishing for firms with high BTC exposure. Traders should watch for whether other mid-market public companies follow suit in de-risking their portfolios, which could temporarily dampen institutional buy-side pressure on Bitcoin.